| Literature DB >> 32078080 |
F E E de Vries1, J D Hodgkinson2,3, J J M Claessen4, O van Ruler5, C A Leo2,3, Y Maeda2,3, O Lapid6, M C Obdeijn6, P J Tanis4, W A Bemelman4, J Constantinides2, G B Hanna3, J Warusavitarne2,3, C Vaizey2,3, M A Boermeester4.
Abstract
PURPOSE: Complex abdominal wall repair (CAWR) in a contaminated operative field is a challenge. Available literature regarding long-term outcomes of CAWR comprises studies that often have small numbers and heterogeneous patient populations. This study aims to assess long-term outcomes of modified-ventral hernia working group (VHWG) grade 3 repairs. Because the relevance of hernia recurrence (HR) as the primary outcome for this patient group is contentious, the need for further hernia surgery (FHS) was also assessed in relation to long-term survival.Entities:
Keywords: Complex; Contamination; Hernia repair; Mesh; Outcomes
Mesh:
Year: 2020 PMID: 32078080 PMCID: PMC7210226 DOI: 10.1007/s10029-020-02124-7
Source DB: PubMed Journal: Hernia ISSN: 1248-9204 Impact factor: 4.739
Patient and operative characteristics of 272 modified VHWG grade 3 procedures in 254 patients
| 272 procedures in 254 patients | |
|---|---|
| Patient characteristics | |
| Age, mean (SD) | 58.0 (SD 13.6) |
| Sex male | 58.8% (160) |
| BMI | Median 26.0 (IQR 22.6–29.6) |
| ASA classification, mean (SD) | Mean 2.43 (SD 0.5) |
| 2 | 59.6% (162) |
| 3 | 37.9% (103) |
| 4 | 2.6% (7) |
| Active smoker | 22.8 (62) |
| Diabetes | 18.4 (50) |
| Immunosuppression | 7.7 (21) |
| Cardiac comorbidity, | 23.2 (63) |
| Pulmonary comorbidity | 20.2 (55) |
| COPD | 10.7 (29) |
| Hypertension | 30.5 (83) |
| IBD | 14.3 (39) |
| Intestinal failure | 47.1 (129) |
| Previous abdominal malignancy | 18.4 (50) |
| History of open abdomen | 47.1 (128) |
| Presence of intestinal fistula | 58.1 (159) |
| Operative characteristics | |
| Number of previous abdominal surgeries, median | 4 (IQR 2–5) (range 1–25) |
| Undergone previous hernia repairs | 43.8 (119) |
| Time since last surgery | Median 349 days (IQR 240–636) |
| CDC wound classification | |
| 2 | 30.1 (82) |
| 3 | 45.6 (124) |
| 4 | 24.3 (66) |
| Anastomosis constructed | 73.5 (200) |
| Mesh removal | 21.7 (59) |
| Component separation technique performed | |
| Yes | 67.3 (183) |
| No | 31.6 (86) |
| Unknown | 1.1 (3) |
| Mesh used | 66.9 (182) |
| Fascial closure | |
| Yes, fascial closure without mesh | 32.4% (88) |
| Yes, reinforcement with mesh | 40.1% (109) |
| No, bridging with mesh | 24.6% (67) |
| Unclear | 2.9% (8) |
BMI body mass index, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease, IBD inflammatory bowel disease, CDC center for disease control and prevention
Fig. 1A Kaplan–Meier depicting overall survival of the cohort at long-term follow-up. Survival is 80% at 5 years and 70% at 10 years
A comparison of operative challenges and choice of mesh (n = 272) in all cases
| ECF with infected mesh | ECF without infected mesh | Infected mesh | Violation of the GI-tracta | Stoma present | Other | Total (%) | |
|---|---|---|---|---|---|---|---|
| No mesh | 13 | 38 | 5 | 34 | 0 | 0 | 90 (33.1) |
| Biologicb | 22 | 44 | 9 | 21 | 1 | 1 | 98 (36.0) |
| Biologic + SAMc | 2 | 3 | 0 | 1 | 0 | 0 | 6 (2.2) |
| Biologic + SNAMd | 0 | 1 | 1 | 2 | 1 | 1 | 6 (2.2) |
| SNAMe | 1 | 2 | 1 | 5 | 10 | 3 | 22 (8.1) |
| SAMf | 2 | 25 | 2 | 5 | 0 | 1 | 35 (12.9) |
| SNAM + SAMg | 1 | 4 | 0 | 7 | 1 | 2 | 15 (5.5) |
| Total (%) | 41 (15.0) | 117 (43.0) | 18 (6.6) | 75 (27.6) | 13 (4.8) | 8 (2.9) | 272 (100) |
ECF enterocutaneous fistula, GI gastrointestinal, SAM synthetic absorbable mesh, SNAM synthetic non-absorbable mesh
afor example bowel resection, enterostomy creation or anastomosis
bMesh used: Strattice
cMesh used: Strattice, vicryl
dMesh used: Strattice, Vypro
eMesh used: Vypro, Ultrpro, Physiomesh, Surgisis, Proceed, Dualmesh, Prolene
fMesh used: Vicryl
gMesh used: Vypro, Vicryl
Mesh associated risk factors for hernia recurrence and further hernia surgery
| Hernia recurrence | Further hernia surgery | |||
|---|---|---|---|---|
| OR (95%CI) | OR (95%CI) | |||
| Mesh type | ||||
| Biologic | 1.27 (0.66–2.46) | 0.48 | 2.40 (0.82–7.02) | 0.11 |
| SNAM | 2.30 (0.95–5.57) | 0.07 | 6.11 (1.82–20.53) | < 0.01 |
| SAM | 5.28 (2.40–11.61) | < 0.01 | 4.45 (1.39–14.24) | 0.01 |
| Mesh position | ||||
| Sublay IA | 1.90 (0.99–3.65) | 0.06 | 2.98 (1.03–8.65) | 0.05 |
| Retrorectus | 1.97 (0.72–5.37) | 0.18 | 2.65 (0.58–12.07) | 0.21 |
| Onlay | 1.79 (0.79–4.04) | 0.16 | 4.07 (1.24–13.36) | 0.02 |
| Bridging IA sublay | 4.22 (1.53–11.60) | < 0.01 | 5.60 (1.44–21.73) | 0.01 |
| Additional mesh | 2.24 (1.06–4.70) | 0.03 | 1.55 (0.62–3.83) | 0.35 |
IA intra-abdominal, SAM synthetic absorbable mesh, SNAM synthetic non-absorbable mesh
Long-term follow-up data demonstrating overall hernia recurrence and further hernia related surgery and divided by repair technique (no mesh, biologic mesh, synthetic mesh) and by ability to achieve fascial closure
| Hernia recurrence | Additional surgery related to hernia recurrence | |||||
|---|---|---|---|---|---|---|
| No bridging | Bridging | Unknown | No bridging | Bridging | Unknown | |
| No mesh | 18/83 = 21.7% | 0/3 | 2/3 | 4/83 = 4.8% | 0/3 | 2/3 |
| Biologic total | 14/69 = 20.3% | 16/35 = 45.7% | 0/2 | 5/69 = 7.2% | 9/35 = 25.7% | 0/2 |
| Biologic onlya | 13/63 = 20.6% | 10/29 = 34.5% | 0/2 | 5/63 = 7.9% | 6/29 = 20.7% | 0/2 |
| Biologic + SAMb | 1/4 | 2/2 | – | 0/4 | 0/2 | – |
| Biologic + SNAMc | 0/2 | 4/4 | – | 0/2 | 3/4 | – |
| Synthetic total | 11/36 = 30.6% | 24/32 = 75% | 1/3 | 6/36 = 16.7% | 9/32 = 28.1% | 1/3 |
| SNAMd | 5/16 = 31.3% | 4/5 | 0/1 | 3/16 = 18.8% | 2/5 | 0/1 |
| SAMe | 5/17 = 29.4% | 15/17 = 88.2% | – | 3/17 = 17.6% | 4/17 = 23.5% | – |
| SNAM + SAMf | 1/3 | 5/10 = 50.0% | 1/2 | 0/3 | 3/10 = 30.0% | 1/2 |
| Total | 43/188 = 22.9% | 40/70 = 57.1% | 3/8 | 15/188 = 8.0% | 18/70 = 25.7% | 3/8 |
SAM synthetic absorbable mesh, SNAM synthetic non-absorbable mesh
aMesh used: Strattice
bMesh used: Strattice, vicryl
cMesh used: Strattice, Vypro
dMesh used: Vypro, Ultrpro, Physiomesh, Surgisis, Proceed, Dualmesh, Prolene
eMesh used: Vicryl
fMesh used: Vypro, Vicryl
Fig. 2A Kaplan–Meier depicting hernia free and hernia surgery free survival. Log rank test demonstrates a significant difference between fascial closure achieved repairs and bridged repairs for both outcomes